Gemcitabine (NCT06710288)

Name: Gemcitabine trial for Platinum-resistant Ovarian Cancer (NCT06710288)
Uploaded: 2026-10-31T22:33:18.378Z
Duration: 1 min 31 s
Description: Gemcitabine trial for Platinum-resistant Ovarian Cancer (NCT06710288). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06710288.

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer: a one-minute explainerNCT067102881 min

Gemcitabine trial for Platinum-resistant Ovarian Cancer (NCT06710288). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for women aged eighteen to eighty-four with platinum-resistant high-grade ovarian, fallopian-tube, or peritoneal cancer after one to three treatment lines, including bevacizumab. Spread outside the abdomen/pelvis or any ascites history excludes participation; biomarker-specific prior-treatment rules also apply.

The idea: collected natural-killer cells become M-CENK. Gemcitabine infusions start first; cell infusions and N-803 injections start in cycle two. N-803 stimulates natural-killer and T cells. Researchers assess tumor response, survival, and safety.

This phase 2 study plans 20 patients. ImmunityBio sponsors; two US sites recruit in El Segundo and Newport Beach.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.